Manufacturing Snag May Stall Portola's Bevyxxa Launch

Company has priced its Factor Xa anticoagulant at $15 per capsule, on par with competitors, and is gearing up for a launch, but it first must resolve manufacturing issues with FDA as it scales up to commercial capacity.

conveyer

Portola Pharmaceuticals Inc. faces a potential setback and further delay for the launch of the Factor Xa anticoagulant Bevyxxa as it works with the US FDA to resolve manufacturing issues related to scaling up commercially.

FDA approved Bevyxxa (betrixiban) on June 23 for prophylaxis (35 to 42 days) of venous thromboembolism in patients hospitalized for...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from New Products

More from Scrip